Randomized study combining interferon and glatiramer acetate in multiple sclerosis-Reference-Cited by-同舟云学术

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

Published:2013-03 Issue:3 Volume:73 Page:327-340
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Lublin Fred D.¹,Cofield Stacey S.²,Cutter Gary R.²,Conwit Robin³,Narayana Ponnada A.⁴,Nelson Flavia⁵,Salter Amber R.²,Gustafson Tarah¹,Wolinsky Jerry S.⁵,

Affiliation:

1. Corinne Goldsmith Dickinson Center for Multiple Sclerosis; Department of Neurology, and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai; New York; NY

2. Department of Biostatistics; University of Alabama at Birmingham; Birmingham; AL

3. National Institute for Neurological Disease and Stroke; National Institutes of Health; Bethesda; MD

4. Department of Diagnostic and Interventional Imaging; University of Texas Health Science Center at Houston; Houston; TX

5. Department of Neurology; University of Texas Health Science Center at Houston; Houston; TX

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference22 articles.

1. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?;Weiner;Ann Neurol,2009

2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial;IFNB Multiple Sclerosis Study Group;Neurology,1993

3. Current and emerging therapies in multiple sclerosis: a systematic review;Castro-Borrero;Ther Adv Neurol Disord,2012

4. Combination therapy in multiple sclerosis;Conway;Lancet Neurol,2010

5. Overlapping and distinct mechanisms of action of multiple sclerosis therapies;Graber;Clin Neurol Neurosurg,2010

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-04

2. An update on combination therapies for multiple sclerosis: where are we now?;Expert Review of Neurotherapeutics;2023-12-02

3. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-11-30

4. The role of myelin in neurodegeneration: implications for drug targets and neuroprotection strategies;Reviews in the Neurosciences;2023-11-22

5. Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset;Multiple Sclerosis Journal;2023-10-13